“…More recently interest in this type of immunotherapy has centred on attempts to immunise lymphocytes in vitro to tumor antigens. This has resulted from the desire to avoid inoculating patients with malignant cells, albeit killed, and the demonstration in animal models that cytotoxic thymus-derived lymphocytes (T cells) can be induced in vitro to tumor-associated antigens (TAA) (McKhann and Jagarlamoody, 1971 a;Wagner and Rollinghoff, 1973;Lundak and Raidt, 1973;Warnatz and Scheiffarth, 1974;Nomoto et al, 1974;Burton et al, 1975;Kuperman et al, 1975;Kall and Hellstrom, 1975;Manson and Palmer, 1975) and that T cells play a major role in the in vivo rejection of malignant tumors . It can also be demonstrated by in vitro tests that cytotoxic human lymphocytes can be induced in vitro to human TAA (Golub and Morton, 1975;McKhann and Jagarlamoody, 1971b;Seigler et al, 1972;Sharma and Terasaki, 1974); however the results of specific adoptive immunotherapy trials, employing human lymphocytes cocultivated in vitro with autochthonous tumor cells, have so far been relatively disappointing (Aust et al, 1970;McKhann and Jagarlamoody, 1971b;Seigler et al, 1972).…”